“Rising Focus on Scalable Manufacturing and Automation”
- One prominent trend in the global lentiviral vector market is the increasing focus on scalable manufacturing processes and automation technologies
- TAs demand for gene therapies grows, manufacturers are investing in advanced bioprocessing solutions to produce high-quality lentiviral vectors at larger scales, ensuring consistent yield and regulatory compliance
- For instance, companies are adopting automated, closed-system platforms for upstream and downstream processing, which enhance production efficiency, reduce contamination risk, and support cGMP standards necessary for clinical and commercial supply
- This trend is also driven by the need to reduce production costs and accelerate time-to-market for gene therapies, prompting strategic partnerships between biotech firms and CDMOs (Contract Development and Manufacturing Organizations)
- Overall, the shift toward scalable and automated manufacturing is transforming the lentiviral vector landscape, enabling broader accessibility of gene therapies and supporting market growth
